- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
To Our Fellow Shareholders, As Chief Executive Officer I want to extend our appreciation for all your support and thoughtfulness during this very sad and sudden transition after the passing […] The post A Letter from the CEO appeared first on ProtoKinetix.
Dalton, OH, November 17, 2025 – ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTC: PKTX), a clinical-stage biomedical company, today deeply regrets to announce our President and Chief Executive Officer […] The post ProtoKinetix Incorporated Mourns the Loss of President and Chief Executive Officer Clarence E. Smith; Appointment of Michael Guzzetta as His Successor appeared first on ProtoKinetix.
Dalton, Ohio, June 6, 2023 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced the submission of a research paper describing cell characterization, graft […] The post Research Paper Incorporating ProtoKinetix AAGP® Submitted to Scientific Journal for Publication appeared first on ProtoKinetix.
Regenerative medicine has had a growing interest in health care, in the past several decades. This type of treatment focuses on engineering tissue to repair, restore and regenerate cells with […] The post How ProtoKinetix Improves Cell Viability Assays in Regenerative Medicine appeared first on ProtoKinetix.
Patients with progressive degenerative eyesight, have been waiting for a cure. For years retinal replacement has been nothing but a wish. But with protoKinetix (PKTX) lives can be changed. PKTX […] The post Change a Life. Invest in Retinal Replacement appeared first on ProtoKinetix.
Marietta, Ohio, July 20, 2022 – ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that the University of Alberta has successfully completed Phase […] The post ProtoKinetix Successfully Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants appeared first on ProtoKinetix.
We risk skin damage every time we step into the sun, whether for work, play, or travel. The sun’s UV rays cause inflammation and sunburns, and sustained damage can lead […] The post Why AAGP is a new method for skin protection appeared first on ProtoKinetix.
Advancements in medical science are making effective treatments more accessible than ever before. In its development of AAGP®, ProtoKinetix is opening the door to new cell therapies, as well as […] The post Evolving Cell Therapies with AAGP appeared first on ProtoKinetix.
The world over, there is increased interest in the possibility of extending human longevity. What could our lives look like if we had more control over our cells? If we […] The post Own the future of anti-aging technology with ProtoKinetix (PKTX) appeared first on ProtoKinetix.
Marietta, Ohio, January 14, 2022- ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it will hold its Annual General Meeting of the […] The post ProtoKinetix Announces Annual General Stockholder Meeting Will Be Held Virtually Only appeared first on ProtoKinetix.